Valeant Pharmaceuticals International Inc. (NYSE: VRS, TSX: VRX) is buying Obagi Medical Products Inc. (Nasdaq: OMPI) for about $360 million.

Obagi develops aesthetic and therapeutic skin-health products, including Obagi Nu-Derm, Condition & Enhance, Obagi-C Rx, Elastiderm and Clenziderm. The company had $120 million in revenue for 2102.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.